English

Molecular Insight Pharmaceuticals, Inc.

EDGAR

Quarterly report (10-Q) · filed 2010-11-04

18 filing records in this dataset, filed from 2007-04-02 to 2010-11-04. Explore the available filing history and original sources.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest fiscal year

Revenue

5.5 million USD

2009 · USD

Exact inputs and evidence

Revenue: 5495073 USD Source

Operating margin

-842.14%

2009 · %

Exact inputs and evidence

Operating Income: -46276435 USD Source
Revenue: 5495073 USD Source

Operating cash flow

-40.8 million USD

2009 · USD

Exact inputs and evidence

Operating Cash Flow: -40765541 USD Source

Free cash flow

-41.7 million USD

2009 · USD

Exact inputs and evidence

Operating Cash Flow: -40765541 USD Source
Capital Expenditure: 912885 USD Source

Cash and cash equivalents: 23.2 million USD 2010-09-30 Source
Exact value

23153968 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2010-11-04.

Financial data available through: 2009-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2009-12-31
Operating income: 6 of 11 periods available· newest 2009-12-31
Net income: 6 of 11 periods available· newest 2009-12-31
Operating cash flow: 6 of 11 periods available· newest 2009-12-31
Capital expenditure: 6 of 11 periods available· newest 2009-12-31
Total assets: 3 of 11 periods available· newest 2009-12-31
liabilities: No compatible figures in this window
Current assets: 3 of 11 periods available· newest 2009-12-31
Current liabilities: 3 of 11 periods available· newest 2009-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2009-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+1,057.9%

Prior period

USD 474,559

2008-01-01 – 2008-12-31
Current period

USD 5.5 million

2009-01-01 – 2009-12-31

Exact inputs and evidence

5495073 − 474559 = 5020514 USD

474559 USD · 2008-01-01 – 2008-12-31
Inspect prior input Prior source
5495073 USD · 2009-01-01 – 2009-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Molecular Insight Pharmaceuticals, Inc. · 2009-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Year-over-year change in Revenue: 5020514 USD Concept: fundies:Revenue Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 5495073 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#7679 Input fundies:Revenue: 474559 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#7679
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 14.77 million

Prior period

−USD 81.25 million

2008-01-01 – 2008-12-31
Current period

−USD 66.48 million

2009-01-01 – 2009-12-31

Exact inputs and evidence

-66483757 − -81253932 = 14770175 USD

-81253932 USD · 2008-01-01 – 2008-12-31
Inspect prior input Prior source
-66483757 USD · 2009-01-01 – 2009-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Molecular Insight Pharmaceuticals, Inc. · 2009-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Year-over-year change in Net income: 14770175 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -66483757 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#9785 Input fundies:NetIncome: -81253932 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#9785
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 15.61 million

Prior period

−USD 56.38 million

2008-01-01 – 2008-12-31
Current period

−USD 40.77 million

2009-01-01 – 2009-12-31

Exact inputs and evidence

-40765541 − -56375139 = 15609598 USD

-56375139 USD · 2008-01-01 – 2008-12-31
Inspect prior input Prior source
-40765541 USD · 2009-01-01 – 2009-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Molecular Insight Pharmaceuticals, Inc. · 2009-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Year-over-year change in Operating cash flow: 15609598 USD Concept: fundies:OperatingCashFlow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -40765541 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10009 Input fundies:OperatingCashFlow: -56375139 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10009
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-17.9%

Prior period

USD 1.11 million

2008-01-01 – 2008-12-31
Current period

USD 912,885

2009-01-01 – 2009-12-31

Exact inputs and evidence

912885 − 1111807 = -198922 USD

1111807 USD · 2008-01-01 – 2008-12-31
Inspect prior input Prior source
912885 USD · 2009-01-01 – 2009-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Molecular Insight Pharmaceuticals, Inc. · 2009-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Year-over-year change in Capital expenditure: -198922 USD Concept: fundies:CapitalExpenditure Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 912885 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10079 Input fundies:CapitalExpenditure: 1111807 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10079
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2009 2009-01-01 – 2009-12-31

Revenue USD 5.5 million 100% of revenue
Cost of revenue USD 35,235 0.6% of revenue
Operating expenses USD 51.77 million 942% of revenue
Other operating costs Derived −USD 35,235 −0.6% of revenue
Operating income −USD 46.28 million −842% of revenue
Tax, interest and other Derived USD 20.21 million 368% of revenue
Net income −USD 66.48 million −1,210% of revenue

Cash

Operating cash flow −USD 40.77 million −742% of revenue
Capital expenditure USD 912,885 17% of revenue
Free cash flow Derived −USD 41.68 million −758% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2007 Operating loss: operating costs were 7,993% of revenue.
2008 Operating loss: operating costs were 13,147% of revenue.
2009 Operating loss: operating costs were 942% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2007 2007-01-01 – 2007-12-31	730672	58405277 Derived	-57674605	2150576 Derived	-59825181	-49770883 Derived	Source 2007-01-01 – 2007-12-31: 730672 USD Inspect Revenue Open source 2007-01-01 – 2007-12-31: -57674605 USD Inspect Operating Income Open source 2007-01-01 – 2007-12-31: -59825181 USD Inspect Net Income Open source 2007-01-01 – 2007-12-31: -44865649 USD Inspect Operating Cash Flow Open source 2007-01-01 – 2007-12-31: 4905234 USD Inspect Capital Expenditure Open source
2008 2008-01-01 – 2008-12-31	474559	62391828 Derived	-61917269	19336663 Derived	-81253932	-57486946 Derived	Source 2008-01-01 – 2008-12-31: 474559 USD Inspect Revenue Open source 2008-01-01 – 2008-12-31: -61917269 USD Inspect Operating Income Open source 2008-01-01 – 2008-12-31: -81253932 USD Inspect Net Income Open source 2008-01-01 – 2008-12-31: -56375139 USD Inspect Operating Cash Flow Open source 2008-01-01 – 2008-12-31: 1111807 USD Inspect Capital Expenditure Open source
2009 2009-01-01 – 2009-12-31	5495073	51771508 Derived	-46276435	20207322 Derived	-66483757	-41678426 Derived	Source 2009-01-01 – 2009-12-31: 5495073 USD Inspect Revenue Open source 2009-01-01 – 2009-12-31: -46276435 USD Inspect Operating Income Open source 2009-01-01 – 2009-12-31: -66483757 USD Inspect Net Income Open source 2009-01-01 – 2009-12-31: -40765541 USD Inspect Operating Cash Flow Open source 2009-01-01 – 2009-12-31: 912885 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 5.5M 2009

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20072007-12-31	Revenue	730672	Revenue: 730672 Open source
20082008-12-31	Revenue	474559	Revenue: 474559 Open source
20092009-12-31	Revenue	5495073	Revenue: 5495073 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

1,057.9% 2009

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20072007-12-31	Year over year	No prior comparable period	Revenue: 730672 Open source
20082008-12-31	Year over year	-35.1%	Revenue: 474559 Open source Revenue: 730672 Open source
20092009-12-31	Year over year	1,057.9%	Revenue: 5495073 Open source Revenue: 474559 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -842.1% 2009

Net margin -1,209.9% 2009

Free cash flow margin -758.5% 2009

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20072007-12-31	Operating margin	-7,893.4%	Operating Income: -57674605 Open source Revenue: 730672 Open source
20082008-12-31	Operating margin	-13,047.3%	Operating Income: -61917269 Open source Revenue: 474559 Open source
20092009-12-31	Operating margin	-842.1%	Operating Income: -46276435 Open source Revenue: 5495073 Open source
20072007-12-31	Net margin	-8,187.7%	Net Income: -59825181 Open source Revenue: 730672 Open source
20082008-12-31	Net margin	-17,122%	Net Income: -81253932 Open source Revenue: 474559 Open source
20092009-12-31	Net margin	-1,209.9%	Net Income: -66483757 Open source Revenue: 5495073 Open source
20072007-12-31	Free cash flow margin	-6,811.7%	Revenue: 730672 Open source Operating Cash Flow: -44865649 Open source Capital Expenditure: 4905234 Open source
20082008-12-31	Free cash flow margin	-12,113.8%	Revenue: 474559 Open source Operating Cash Flow: -56375139 Open source Capital Expenditure: 1111807 Open source
20092009-12-31	Free cash flow margin	-758.5%	Revenue: 5495073 Open source Operating Cash Flow: -40765541 Open source Capital Expenditure: 912885 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -40.8M 2009

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20072007-12-31	Operating cash flow	-44865649	Operating Cash Flow: -44865649 Open source
20082008-12-31	Operating cash flow	-56375139	Operating Cash Flow: -56375139 Open source
20092009-12-31	Operating cash flow	-40765541	Operating Cash Flow: -40765541 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -41.7M 2009

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20072007-12-31	Free cash flow	-49770883	Operating Cash Flow: -44865649 Open source Capital Expenditure: 4905234 Open source
20082008-12-31	Free cash flow	-57486946	Operating Cash Flow: -56375139 Open source Capital Expenditure: 1111807 Open source
20092009-12-31	Free cash flow	-41678426	Operating Cash Flow: -40765541 Open source Capital Expenditure: 912885 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2007-12-31	Liabilities / assets	Not reported	Total Assets: 176701873 Open source
2008-12-31	Liabilities / assets	Not reported	Total Assets: 119176955 Open source
2009-12-31	Liabilities / assets	Not reported	Total Assets: 74606385 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.38× 2009

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20072007-12-31	Current assets / current liabilities	8.06×	Current Assets: 121008755 Open source Current Liabilities: 15013121 Open source
20082008-12-31	Current assets / current liabilities	8.73×	Current Assets: 101218009 Open source Current Liabilities: 11588419 Open source
20092009-12-31	Current assets / current liabilities	0.38×	Current Assets: 70061897 Open source Current Liabilities: 184600269 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2004 2004-01-01 – 2004-12-31	−USD 8.32 million Exact value Exact value: -8315403 USD 2004-01-01 – 2004-12-31: -8315403 USD Inspect Net Income Open source Share or cite Citation for Net Income · Molecular Insight Pharmaceuticals, Inc. · 2004-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Net Income: -8315403 USD Concept: fundies:NetIncome Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3ANetIncome&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8315403 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-07-002021.txt#27388 The citation records this snapshot. The page link may show a newer release later.	−USD 6.17 million Exact value Exact value: -6167335 USD 2004-01-01 – 2004-12-31: -6167335 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Molecular Insight Pharmaceuticals, Inc. · 2004-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Operating Cash Flow: -6167335 USD Concept: fundies:OperatingCashFlow Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3AOperatingCashFlow&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6167335 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-07-002021.txt#28176 The citation records this snapshot. The page link may show a newer release later.	USD 202,542 Exact value Exact value: 202542 USD 2004-01-01 – 2004-12-31: 202542 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Molecular Insight Pharmaceuticals, Inc. · 2004-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Capital Expenditure: 202542 USD Concept: fundies:CapitalExpenditure Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3ACapitalExpenditure&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 202542 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-07-002021.txt#28455 The citation records this snapshot. The page link may show a newer release later.	−USD 6.37 million Calculation and evidence -6167335 − 202542 USD Exact free cash flow: -6369877 USD 2004-01-01 – 2004-12-31: -6167335 USD · Inspect Operating Cash Flow · Source 2004-01-01 – 2004-12-31: 202542 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Molecular Insight Pharmaceuticals, Inc. · 2004-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Free cash flow: -6369877 USD Concept: free-cash-flow Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6167335 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-07-002021.txt#28176 Input fundies:CapitalExpenditure: 202542 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-07-002021.txt#28455 The citation records this snapshot. The page link may show a newer release later.
2005 2005-01-01 – 2005-12-31	−USD 18.3 million Exact value Exact value: -18300820 USD 2005-01-01 – 2005-12-31: -18300820 USD Inspect Net Income Open source Share or cite Citation for Net Income · Molecular Insight Pharmaceuticals, Inc. · 2005-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Net Income: -18300820 USD Concept: fundies:NetIncome Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3ANetIncome&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18300820 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-08-002206.txt#31841 The citation records this snapshot. The page link may show a newer release later.	−USD 14.21 million Exact value Exact value: -14208795 USD 2005-01-01 – 2005-12-31: -14208795 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Molecular Insight Pharmaceuticals, Inc. · 2005-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Operating Cash Flow: -14208795 USD Concept: fundies:OperatingCashFlow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3AOperatingCashFlow&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14208795 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-08-002206.txt#32666 The citation records this snapshot. The page link may show a newer release later.	USD 226,945 Exact value Exact value: 226945 USD 2005-01-01 – 2005-12-31: 226945 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Molecular Insight Pharmaceuticals, Inc. · 2005-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Capital Expenditure: 226945 USD Concept: fundies:CapitalExpenditure Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3ACapitalExpenditure&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 226945 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-08-002206.txt#32939 The citation records this snapshot. The page link may show a newer release later.	−USD 14.44 million Calculation and evidence -14208795 − 226945 USD Exact free cash flow: -14435740 USD 2005-01-01 – 2005-12-31: -14208795 USD · Inspect Operating Cash Flow · Source 2005-01-01 – 2005-12-31: 226945 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Molecular Insight Pharmaceuticals, Inc. · 2005-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Free cash flow: -14435740 USD Concept: free-cash-flow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14208795 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-08-002206.txt#32666 Input fundies:CapitalExpenditure: 226945 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-08-002206.txt#32939 The citation records this snapshot. The page link may show a newer release later.
2006 2006-01-01 – 2006-12-31	−USD 27.27 million Exact value Exact value: -27266218 USD 2006-01-01 – 2006-12-31: -27266218 USD Inspect Net Income Open source Share or cite Citation for Net Income · Molecular Insight Pharmaceuticals, Inc. · 2006-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Net Income: -27266218 USD Concept: fundies:NetIncome Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3ANetIncome&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27266218 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-09-001741.txt#32666 The citation records this snapshot. The page link may show a newer release later.	−USD 22.09 million Exact value Exact value: -22094573 USD 2006-01-01 – 2006-12-31: -22094573 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Molecular Insight Pharmaceuticals, Inc. · 2006-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Operating Cash Flow: -22094573 USD Concept: fundies:OperatingCashFlow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3AOperatingCashFlow&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22094573 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-09-001741.txt#33546 The citation records this snapshot. The page link may show a newer release later.	USD 716,605 Exact value Exact value: 716605 USD 2006-01-01 – 2006-12-31: 716605 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Molecular Insight Pharmaceuticals, Inc. · 2006-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Capital Expenditure: 716605 USD Concept: fundies:CapitalExpenditure Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3ACapitalExpenditure&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 716605 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-09-001741.txt#33819 The citation records this snapshot. The page link may show a newer release later.	−USD 22.81 million Calculation and evidence -22094573 − 716605 USD Exact free cash flow: -22811178 USD 2006-01-01 – 2006-12-31: -22094573 USD · Inspect Operating Cash Flow · Source 2006-01-01 – 2006-12-31: 716605 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Molecular Insight Pharmaceuticals, Inc. · 2006-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Free cash flow: -22811178 USD Concept: free-cash-flow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22094573 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-09-001741.txt#33546 Input fundies:CapitalExpenditure: 716605 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0000950135-09-001741.txt#33819 The citation records this snapshot. The page link may show a newer release later.
2007 2007-01-01 – 2007-12-31	−USD 59.83 million Exact value Exact value: -59825181 USD 2007-01-01 – 2007-12-31: -59825181 USD Inspect Net Income Open source Share or cite Citation for Net Income · Molecular Insight Pharmaceuticals, Inc. · 2007-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Net Income: -59825181 USD Concept: fundies:NetIncome Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3ANetIncome&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:NetIncome: -59825181 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#9785 The citation records this snapshot. The page link may show a newer release later.	−USD 44.87 million Exact value Exact value: -44865649 USD 2007-01-01 – 2007-12-31: -44865649 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Molecular Insight Pharmaceuticals, Inc. · 2007-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Operating Cash Flow: -44865649 USD Concept: fundies:OperatingCashFlow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3AOperatingCashFlow&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -44865649 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10009 The citation records this snapshot. The page link may show a newer release later.	USD 4.91 million Exact value Exact value: 4905234 USD 2007-01-01 – 2007-12-31: 4905234 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Molecular Insight Pharmaceuticals, Inc. · 2007-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Capital Expenditure: 4905234 USD Concept: fundies:CapitalExpenditure Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3ACapitalExpenditure&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4905234 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10079 The citation records this snapshot. The page link may show a newer release later.	−USD 49.77 million Calculation and evidence -44865649 − 4905234 USD Exact free cash flow: -49770883 USD 2007-01-01 – 2007-12-31: -44865649 USD · Inspect Operating Cash Flow · Source 2007-01-01 – 2007-12-31: 4905234 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Molecular Insight Pharmaceuticals, Inc. · 2007-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Free cash flow: -49770883 USD Concept: free-cash-flow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -44865649 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10009 Input fundies:CapitalExpenditure: 4905234 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10079 The citation records this snapshot. The page link may show a newer release later.
2008 2008-01-01 – 2008-12-31	−USD 81.25 million Exact value Exact value: -81253932 USD 2008-01-01 – 2008-12-31: -81253932 USD Inspect Net Income Open source Share or cite Citation for Net Income · Molecular Insight Pharmaceuticals, Inc. · 2008-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Net Income: -81253932 USD Concept: fundies:NetIncome Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3ANetIncome&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:NetIncome: -81253932 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#9785 The citation records this snapshot. The page link may show a newer release later.	−USD 56.38 million Exact value Exact value: -56375139 USD 2008-01-01 – 2008-12-31: -56375139 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Molecular Insight Pharmaceuticals, Inc. · 2008-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Operating Cash Flow: -56375139 USD Concept: fundies:OperatingCashFlow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3AOperatingCashFlow&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -56375139 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10009 The citation records this snapshot. The page link may show a newer release later.	USD 1.11 million Exact value Exact value: 1111807 USD 2008-01-01 – 2008-12-31: 1111807 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Molecular Insight Pharmaceuticals, Inc. · 2008-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Capital Expenditure: 1111807 USD Concept: fundies:CapitalExpenditure Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3ACapitalExpenditure&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1111807 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10079 The citation records this snapshot. The page link may show a newer release later.	−USD 57.49 million Calculation and evidence -56375139 − 1111807 USD Exact free cash flow: -57486946 USD 2008-01-01 – 2008-12-31: -56375139 USD · Inspect Operating Cash Flow · Source 2008-01-01 – 2008-12-31: 1111807 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Molecular Insight Pharmaceuticals, Inc. · 2008-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Free cash flow: -57486946 USD Concept: free-cash-flow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -56375139 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10009 Input fundies:CapitalExpenditure: 1111807 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10079 The citation records this snapshot. The page link may show a newer release later.
2009 2009-01-01 – 2009-12-31	−USD 66.48 million Exact value Exact value: -66483757 USD 2009-01-01 – 2009-12-31: -66483757 USD Inspect Net Income Open source Share or cite Citation for Net Income · Molecular Insight Pharmaceuticals, Inc. · 2009-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Net Income: -66483757 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3ANetIncome&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:NetIncome: -66483757 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#9785 The citation records this snapshot. The page link may show a newer release later.	−USD 40.77 million Exact value Exact value: -40765541 USD 2009-01-01 – 2009-12-31: -40765541 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Molecular Insight Pharmaceuticals, Inc. · 2009-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Operating Cash Flow: -40765541 USD Concept: fundies:OperatingCashFlow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3AOperatingCashFlow&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -40765541 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10009 The citation records this snapshot. The page link may show a newer release later.	USD 912,885 Exact value Exact value: 912885 USD 2009-01-01 – 2009-12-31: 912885 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Molecular Insight Pharmaceuticals, Inc. · 2009-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Capital Expenditure: 912885 USD Concept: fundies:CapitalExpenditure Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752/explain?concept=fundies%3ACapitalExpenditure&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 912885 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10079 The citation records this snapshot. The page link may show a newer release later.	−USD 41.68 million Calculation and evidence -40765541 − 912885 USD Exact free cash flow: -41678426 USD 2009-01-01 – 2009-12-31: -40765541 USD · Inspect Operating Cash Flow · Source 2009-01-01 – 2009-12-31: 912885 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Molecular Insight Pharmaceuticals, Inc. · 2009-12-31 Molecular Insight Pharmaceuticals, Inc. (edgar:1340752) Free cash flow: -41678426 USD Concept: free-cash-flow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T17:00:33Z Snapshot: b81e09c17fdb2065edee3688d15fc16477506bb2e2e7ce3896cd5019554c3193 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1340752?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -40765541 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10009 Input fundies:CapitalExpenditure: 912885 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1340752/0001193125-10-058373.txt#10079 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

18 filings · 0 latest values · 0 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001340752, 1340752, edgar:1340752

Molecular Insight Pharmaceuticals, Inc.

Latest fiscal year

Revenue

Operating margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2009 2009-01-01 – 2009-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation